tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

HBM Holdings to Present Promising Cancer Therapy Data at ESMO 2025

Story Highlights
HBM Holdings to Present Promising Cancer Therapy Data at ESMO 2025

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

HBM Holdings Ltd. ( (HK:2142) ) has shared an update.

HBM Holdings Ltd. announced that it will present Phase II clinical data for its anti-CTLA-4 antibody, porustobart (HBM4003), in combination with tislelizumab, at the ESMO Congress 2025. This presentation will highlight the efficacy and safety of the treatment for microsatellite stable metastatic colorectal cancer, potentially enhancing the company’s position in the oncology market.

More about HBM Holdings Ltd.

HBM Holdings Ltd. operates in the biotechnology industry, focusing on the development of innovative antibody therapies. The company specializes in fully human heavy-chain-only antibodies, with a market focus on treating various solid tumors using advanced therapeutic platforms.

Average Trading Volume: 10,054,526

Technical Sentiment Signal: Buy

Current Market Cap: HK$8.03B

For an in-depth examination of 2142 stock, go to TipRanks’ Overview page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1